Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-04-11
2006-04-11
Foley, Shanon (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S186100, C536S023100, C536S023720
Reexamination Certificate
active
07025969
ABSTRACT:
This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAs, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments of the invention relate to methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors.
REFERENCES:
patent: 3959466 (1976-05-01), Plotkin
patent: 4058598 (1977-11-01), Stern et al.
patent: 4689225 (1987-08-01), Pereira
patent: 4716104 (1987-12-01), Harris et al.
patent: 4762780 (1988-08-01), Spector et al.
patent: 5075213 (1991-12-01), Pande et al.
patent: 5180813 (1993-01-01), Stinski
patent: 5248768 (1993-09-01), Lussenhop et al.
patent: 6074645 (2000-06-01), Diamond et al.
patent: 6156317 (2000-12-01), Diamond et al.
Pande, H., et al., “Structural Analysis of a 64-kDa Major Structural Protein of Human Cytomegalovirus (Towne): Identification of a Phosphorylation Site and Comparison to pp65 of HCMV (AD169),”Virology, vol. 178, pp. 6-14, 1980.
Meyers, J.D., et al., “Risk Factors for Cytomegalovirus Infection After Human Marrow Transplantation,”The Journal of Infectious Diseases, vol. 153, No. 3, pp. 478-488, Mar. 1986.
Quinnan, G.V., Jr., et al., “Cytotoxic T Cells in Cytomegalovirus Infection; HLA-Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients,”The New England Journal of Medicine, vol. 307, No. 1, Jul. 1, 1982, pp. 7-13.
Pande, H., et al., Human Cytomegalovirus Strain Towne pp65 Gene: Nucleotide Sequence and Expression inEscherichia coli, Virology, vol. 182, pp. 220-228, 1991.
McLaughlin-Taylor, E., et al., “Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8+ Virus-Specific Cytotoxic T Lymphocytes,”Journal of Medical Virology, vol. 43, pp. 103-110, 1994.
Walter, E.A., et al., “Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor,”The New England Journal of Medicine, pp. 1038-1044, Oct. 19, 1995, vol. 333, No. 16.
Borysiewicz, L.K., et al., “Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity,”Eur. J. Immunol., vol. 13, pp. 804-809, 1983.
Zhou, Y.F., et al., “Association Between Prior Cytomegalovirus Infection and the Risk of Restinosis After Coronary Atherectomy,”The New England Journal of Medicine, pp. 624-630 Aug. 29, 1996.
Speir, Edith, et al., “Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restinosis,”Science, vol. 265, pp. 391-394, Jul. 15, 1994.
Li, C.-R. et al., “Recovery of HLA-Restricted Cytomegalovirus (CMV)-Specific T-Cell Responses After Allogeneic Bone Marrow Transplant: Correlation with CMV Disease and Effect of Ganciclovir Prophylaxis,”Blood, vol. 83, No. 7, pp. 1971-1979, Apr. 1, 1994.
Goodrich, J.M., et al., “Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation,”The New England Journal of Medicine, vol. 325, No. 23, pp. 1601-1607, Dec. 5, 1991.
Reusser, P., et al., “Cytotoxic T-Lymphocyte Response to Cytomegalovirus After Human Allogeneic Bone Marrow Transplantation: Pattern of Recovery and Correlation With Cytomegalovirus Infection and Disease,”Blood, vol. 78, No. 5, pp. 1373-1380, Sep. 1, 1991.
Wills, M.R., et al., “The Human Cytotoxic T-Lymphocyte (CTL) Response to Cytomegalovirus Is Dominated by Structural Protein pp65: Frequency, Specificity, and T-Cell Receptor Usage of pp65-Specific CTL,”Journal of Virology, pp. 7569-7579, Nov. 1996.
Gilbert, M.J., et al., “Selective Interference with Class I major Histocompatability Complex Presentation of the Major Immediate-Early Protein following Infection with Human Cytomegalovirus,”Journal of Virology, pp. 3461-3469, Jun. 1993, vol. 67, No. 6.
Goodrich, J.M., et al., “Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease After Allogeneic Marrow Transplant,”Annals of Internal Medicine, vol. 118, pp. 173-178, 1993.
Schmidt, G.M., et al., “A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants,”The New England Journal of Medicine, vol. 324, No. 15, pp. 1005-1011, Apr. 11, 1991.
Rasmussen, L., “Immune Response to Human Cytomegalovirus Infection,”Current Topics in Microbiology and Immunology, vol. 154, pp. 221-255, 1990.
Forman, S.J., et al., “A 64,000 Dalton Matrix Protein of Human Cytomegalovirus Induces in Vitro Immune Responses Similar to Those of Whole Viral Antigen,”The Journal of Immunology, vol. 134, No. 5, pp. 3391-3395, May 1985.
Borysiewicz, L.K., et al., “Human Cytomegalovirus-Specific Cytotoxic T Cells—Relative Frequency of Stage-specific CTL Recognizing the 72kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses,”J. Exp. Med., vol. 168, pp. 919-931, Sep. 1988.
Diamond, D.J., et al., “Development of A Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection,”Blood, vol. 90, No. 5, pp. 1751-1767, Sep. 1, 1997.
Winston, D.J., et al., “Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients—Results of a Placebo-Controlled, Double-Blind Trial,”Annals of Internal Medicine, vol. 118, pp. 179-184, 1993.
Greenberg, P.D., et al., “Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor-Derived CMV-Specific T Cell Clones Expanded In Vitro,”Annals New York Academy of Sciences, vol. 636, pp. 184-195, 1991.
Ohlin, M., et al., “Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus,”Clin. Exp. Immunol., vol. 84, pp. 508-514, 1991.
Rüger, B., et al., “Primary Structure and Transcription of the Genes Coding for the Two Virion Phosphoproteins pp65 and pp71 of Human Cytomegalovirus,”Journal of Virology, pp. 446-453, Feb. 1987, vol. 61, No. 2.
Boppana, S.B., et al., “Recognition of Human Cytomegalovirus Gene Products by HCMV-Specific Cytotoxic T Cells,”Virology, vol. 222, pp. 293-296, 1996.
Irmiere, A., et al., “Isolation and Characterization of a Noninfectious Virion-like Particle Released from Cells Infected with Human Strains of Cytomegalovirus,”Virology, vol. 130, pp. 118-133, 1983.
Retiére, C., et al., “Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool To Study the Fine Specificity of the Antiviral Response,”Journal of Virology, pp. 3948-3952, May 2000, vol. 74, No. 9.
Kern, Fi., et al., “Target Structures of the CD8+-T-Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited,”Journal of Virology, pp. 8179-8184, Oct. 1999, vol. 73, No. 10.
Gyulai, Z., et al., “Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1 Specific CTLS,”The Journal of Infectious Diseases, vol. 181, pp. 1537-1546, 2000.
Periera. L., et al., “Monoclonal Antibodies to Human Cytomegalovirus: Three Surface Membrane Proteins with Unique Immunological and Electrophoretic Properties Specify Cross-Reactive Deter
Hawkins Ghislaine
Zaia John A.
City of Hope
Foley Shanon
Rothwell, Figg, Ernst & Manbeck pc
LandOfFree
Protein kinase deficient, immunologically active CMVpp65... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase deficient, immunologically active CMVpp65..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase deficient, immunologically active CMVpp65... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586086